Vnitr Lek 2011, 57(4):396-401

Metabolic surgery - the most effective diabetes treatment

P. Sucharda
III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Bariatric operations resulting in a favourable metabolic effect - not only due to a reduction of excessive body weight - are known as metabolic surgery. Interventions into the digestive tract, especially the prevented contact of food with the duodenal and proximal jejunal lining and/or the effect of an insufficiently digested food on the jejunum, favourably affect incretin mechanisms. Thus, "resolution" of type 2 diabetes and discontinuation of antidiabetic medication can be achieved in as many as 95 percent of patients. Today, combined procedures (gastric bypass, biliopancreatic diversion) are indicated for diabetic subjects with severe obesity. The usefulness and indication of metabolic surgery for type 2 diabetics with less pronounced overweight have to be verified in prospective controlled studies.

Keywords: obesity; surgery; diabetes; incretin

Received: November 7, 2010; Published: April 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sucharda P. Metabolic surgery - the most effective diabetes treatment. Vnitr Lek. 2011;57(4):396-401.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Li R, Zhang P, Barker LE et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010; 33: 1872-1894. Go to original source... Go to PubMed...
    2. Keating CL, Dixon JB, Moodie ML et al. Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes: a randomized controlled trial. Diabetes Care 2009; 32: 580-584. Go to original source... Go to PubMed...
    3. Hoerger TJ, Zhang P, Segel JE et al. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care 2010; 33: 1933-1939. Go to original source... Go to PubMed...
    4. Kremen AJ, Linner JH, Nelson CH. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Am Surg 1954; 140: 439-448. Go to original source... Go to PubMed...
    5. Buchwald H, Rucker RD. The history of metabolic surgery for morbid obesity and a commentary. World J Surg 1981; 5: 781-787. Go to original source... Go to PubMed...
    6. Mason EE, Ito C. Gastric bypass in obesity. Surg Clin North Am 1967; 47: 1345-1351. Go to original source... Go to PubMed...
    7. Pešková M, Šonka J, Sucharda P. Gastroplastika k redukci tělesné hmotnosti. Čas Lék Česk 1987; 126: 847-850. Go to PubMed...
    8. Fried M. Moderní chirurgické metody léčby obezity. Praha: Grada Publishig 2005.
    9. Scopinaro N, Gianetta E, Civalleri D et al. Two years of clinical experience with biliopancreatic bypass for obesity. Am J Clin Nutr 1980; 33 (2 Suppl): 506-514. Go to original source... Go to PubMed...
    10. Baltasar A, Serra C, Pérez N et al. Laparoscopic sleeve gastrectomy: a multi-purpose bariatric operation. Obes Surg 2005; 15: 1124-1128. Go to original source... Go to PubMed...
    11. Ramos A, Galvao Neto M, Galvao M et al. Laparoscopic greater curvature plication: initial results of an alternative restrictive bariatric procedure. Obes Surg 2010; 20: 913-918. Go to original source... Go to PubMed...
    12. Buchwald H. Lowering of cholesterol absorption and blood levels by ileal exclusion: experimental basis and preliminary clinical report. Circulation 1964; 29: 713-720. Go to original source... Go to PubMed...
    13. Buchwald H, Varco RL (eds). Metabolic surgery. New York: Grune & Stratton 1978.
    14. Scopinaro N, Papadia F, Marinari G et al. Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI < 35 kg/m2. Obes Surg 2007; 17: 185-192. Go to original source... Go to PubMed...
    15. Fried M, Ribaric G, Buchwald JN et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI < 35 kg/m2: an integrative review of early studies. Obes Surg 2010; 20: 776-790. Go to original source... Go to PubMed...
    16. Ackerman NB. Observations on the improvements in carbohydrate metabolism in diabetic and other morbidly obese patients after jejunoileal bypass. Surg Gynecol Obstet 1981; 152: 581-586.
    17. Pories WJ, Caro JF, Flickinger EG et al. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 1987; 206: 316-323. Go to original source... Go to PubMed...
    18. Pories WJ, MacDonald KG Jr, Flickinger EG et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992; 215: 633-642. Go to original source... Go to PubMed...
    19. Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339-350. Go to original source... Go to PubMed...
    20. Sjöström L, Narbro K, Sjöström CD et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752. Go to original source... Go to PubMed...
    21. Sjöström L, Lindroos AK, Peltonen M et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693. Go to original source... Go to PubMed...
    22. Adams TD, Gress RE, Smith SC et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753-761. Go to original source... Go to PubMed...
    23. Adrian TE, Denham EW, Prystowsky JB. The gut hormones and their roles in obesity and gastric restrictive surgery. Curr Opin Endocrinol Diabetes 2003; 10: 322-329. Go to original source...
    24. Ashrafian H, le Roux CW. Metabolic surgery and gut hormones - A review of bariatric entero-humoral modulation. Physiol Behav 2009; 97: 620-631. Go to original source... Go to PubMed...
    25. Knop FK, Vilsbøll T, Højberg PV et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-1959. Go to original source... Go to PubMed...
    26. Gault VA, Irwin N, Green BD et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 2005; 54: 2436-2446. Go to original source... Go to PubMed...
    27. Irwin N, McClean PL, Patterson S et al. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Biol Chem 2009; 390: 75-80. Go to original source... Go to PubMed...
    28. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002; 236: 554-559. Go to original source... Go to PubMed...
    29. Rubino F, Forgione A, Cummings DE et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006; 244: 741-749. Go to original source... Go to PubMed...
    30. Rodriguez-Grunert L, Galvao Neto MP, Alamo M et al. First human experiance with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis 2008; 4: 55-59. Go to original source... Go to PubMed...
    31. Schouten R, Rijs CS, Bouvy ND et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 2010; 251: 236-243. Go to original source... Go to PubMed...
    32. DePaula AL, Stival AR, Halpern A et al. Surgical treatment of morbid obesity: mid-term outcomes of the laparoscopic ileal interposition associated to a sleeve gastrectomy in 120 Patients. Obes Surg 2010 Jul 23. [Epub ahead of print]. Go to original source... Go to PubMed...
    33. Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs? Diab Vasc Dis Res 2007; 4: 151-153. Go to original source... Go to PubMed...
    34. Flatt PR. Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes? Diabet Med 2008; 25: 759-764. Go to original source... Go to PubMed...
    35. Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 2009; 52: 2270-2276. Go to original source... Go to PubMed...
    36. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248-256. Go to original source... Go to PubMed...
    37. Rubino F, Schauer PR, Kaplan LM et al. Metabolic surgery to treat type 2 diabetes: Clinical Outcomes and mechanisms of action. Annu Rev Med 2010; 61: 393-411. Go to original source... Go to PubMed...
    38. Vetter ML, Cardillo S, Rickels MR et al. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009; 150: 94-103. Go to original source... Go to PubMed...
    39. Hussain A, Mahmood H, El-Hasani S. Can Roux-en-Y gastric bypass provide a lifelong solution for diabetes mellitus? Can J Surg 2009; 52: E269-E275.
    40. Kashyap SR, Gatmaitan P, Brethauer S et al. Bariatric surgery for type 2 diabetes: weighing the impact for obese patients. Cleve Clin J Med 2010; 77: 468-476. Go to original source... Go to PubMed...
    41. Gill RS, Birch DW, Shi X et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis 2010; 6: 707-713. Go to original source... Go to PubMed...
    42. Fried M, Hainer V, Basdevant A et al. Interdisciplinární evropská závazná doporučení pro chirurgickou léčbu těžké obezity. Vnitř Lék 2008; 54: 421-429. Go to PubMed...
    43. American Diabetes Association. Executive summary: Standards of medical care in diabetes - 2010. Diabetes Care 2010; 33 (Suppl 1): S4-S10. Go to original source... Go to PubMed...
    44. Daousi C, Casson IF, Gill GV et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006; 82: 280-284. Go to original source... Go to PubMed...
    45. Schulman AP, Del Genio F, Sinha N et al. "Metabolic" surgery for the treatment of type 2 diabetes mellitus. Endocr Pract 2009; 15: 624-631. Go to original source... Go to PubMed...
    46. DePaula AL, Stival AR, DePaula CC et al. Impact on dyslipidemia of the laparoscopic ileal interposition associated to sleeve gastrectomy in type 2 diabetic patients. J Gastrointest Surg 2010; 14: 1319-1325. Go to original source... Go to PubMed...
    47. DePaula AL, Macedo AL, Mota BR et al. Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29. Surg Endosc 2009; 23: 1313-1320. Go to original source... Go to PubMed...
    48. Pinkney JH, Johnson AB, Gale EA. The big fat bariatric bandwagon. Diabetologia 2010; 53: 1815-1822. Go to original source... Go to PubMed...
    49. DiGiorgi M, Rosen DJ, Choi JJ et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 2010; 6: 249-253. Go to original source... Go to PubMed...
    50. Hall TC, Pellen MG, Sedman PC et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg 2010; 20: 1245-1250. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.